Literature DB >> 20711232

Regulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cells.

B B Olsen1, O-G Issinger, B Guerra.   

Abstract

The DNA-dependent protein kinase (DNA-PK) is a nuclear serine/threonine protein kinase composed of a large catalytic subunit (DNA-PKcs) and a heterodimeric DNA-targeting subunit Ku. DNA-PK is a major component of the nonhomologous end-joining pathway of DNA double-strand breaks repair. Although DNA-PK has been biochemically characterized in vitro, relatively little is known about its functions in the context of DNA repair and how its kinase activity is precisely regulated in vivo. Here, we report that cellular depletion of the individual catalytic subunits of protein kinase CK2 by RNA interference leads to significant cell death in M059K human glioblastoma cells expressing DNA-PKcs, but not in their isogenic counterpart, that is M059J cells, devoid of DNA-PKcs. The lack of CK2 results in enhanced DNA-PKcs activity and strongly inhibits DNA damage-induced autophosphorylation of DNA-PKcs at S2056 as well as repair of DNA double-strand breaks. By the application of the in situ proximity ligation assay, we show that CK2 interacts with DNA-PKcs in normal growing cells and that the association increases upon DNA damage. These results indicate that CK2 has an important role in the modulation of DNA-PKcs activity and its phosphorylation status providing important insights into the mechanisms by which DNA-PKcs is regulated in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20711232     DOI: 10.1038/onc.2010.337

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  DNA-PK: a dynamic enzyme in a versatile DSB repair pathway.

Authors:  Anthony J Davis; Benjamin P C Chen; David J Chen
Journal:  DNA Repair (Amst)       Date:  2014-03-27

2.  Lack of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is accompanied by increased CK2α' levels.

Authors:  Birgitte B Olsen; Ulrike Fischer; Tine L Rasmussen; Matthias Montenarh; Eckart Meese; Gerhard Fritz; Olaf-Georg Issinger
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

3.  Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells.

Authors:  Maya Agarwal; Ryan T Nitta; Gordon Li
Journal:  J Mol Genet Med       Date:  2013-12-09

Review 4.  Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity.

Authors:  Odile Filhol; Sofia Giacosa; Yann Wallez; Claude Cochet
Journal:  Cell Mol Life Sci       Date:  2015-05-20       Impact factor: 9.261

5.  Sublethal doses of β-amyloid peptide abrogate DNA-dependent protein kinase activity.

Authors:  Alessio Cardinale; Mauro Racaniello; Serena Saladini; Giovanna De Chiara; Cristiana Mollinari; Maria Chiara de Stefano; Maurizio Pocchiari; Enrico Garaci; Daniela Merlo
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

6.  Protein kinase CK2 regulates redox homeostasis through NF-κB and Bcl-xL in cardiomyoblasts.

Authors:  Susanne Schaefer; Barbara Guerra
Journal:  Mol Cell Biochem       Date:  2017-06-08       Impact factor: 3.396

7.  Identification of a novel protein interaction motif in the regulatory subunit of casein kinase 2.

Authors:  Jennifer Yinuo Cao; Kathy Shire; Cameron Landry; Gerald D Gish; Tony Pawson; Lori Frappier
Journal:  Mol Cell Biol       Date:  2013-11-11       Impact factor: 4.272

Review 8.  Beyond DNA repair: DNA-PK function in cancer.

Authors:  Jonathan F Goodwin; Karen E Knudsen
Journal:  Cancer Discov       Date:  2014-08-28       Impact factor: 39.397

9.  Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.

Authors:  Ying Zheng; Braden C McFarland; Denis Drygin; Hao Yu; Susan L Bellis; Hyunsoo Kim; Markus Bredel; Etty N Benveniste
Journal:  Clin Cancer Res       Date:  2013-09-13       Impact factor: 12.531

Review 10.  Targeting CK2-driven non-oncogene addiction in B-cell tumors.

Authors:  E Mandato; S Manni; F Zaffino; G Semenzato; F Piazza
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.